When pursuing a Biologics License Application (BLA) or New Drug Application (NDA), meeting timelines is crucial. However, the path to approval is often fraught with potential delays. Understanding these risks—and knowing how to mitigate them—can make or break your timeline.

Top 10 most common risks and expert tips on how to manage them effectively

1. Incomplete or Inaccurate Submission

One of the most common pitfalls is submitting an incomplete or inaccurate application, which can trigger a Refuse to File (RTF) action by the FDA. An RTF delays the entire process by months.

Expert Tip: Conduct a detailed pre-submission checklist review and ensure all required data and documents are included. Invest in regulatory strategists/planners and regulatory medical writers who specialize in meticulous document preparation and ensure thorough quality control (QC) checks.

2. Lack of Early FDA Engagement

Many companies fail to engage with the FDA early in the development process. Without early communication, the risk of misaligned expectations on clinical and regulatory requirements increases.

Expert Tip: Utilize various meeting types available, as appropriate to the meeting topic, to clarify regulatory expectations and study designs. Early interaction helps in understanding the FDA’s perspective and avoiding unnecessary revisions and delays.

3. Unresolved CMC (Chemistry, Manufacturing, and Controls) Issues

Manufacturing-related issues, such as inconsistent batch production or lack of robust validation data, can lead to significant delays in your timeline.

Expert Tip: Start CMC planning early and involve CMC experts during development. Ensure the production process is scalable, validated, and compliant with Good Manufacturing Practices (GMP). Make sure your CMC experts are involved in and aligned with the submission strategy and overall business goals.

4. Inadequate Clinical Data

Failing to provide compelling clinical data, including efficacy, safety, and quality of life, can slow down the review process or lead to additional studies being required.

Expert Tip: Collaborate with statisticians and clinical trial experts to ensure your clinical data package is robust and aligned with regulatory guidelines. In correspondence with health authorities, make sure your clinical strategy is well supported with information and data and is outlined in detail. A well-executed clinical trial strategy minimizes surprises during the review.

5. Data Integrity Issues

Ensuring data integrity across all clinical and nonclinical studies is critical. Data discrepancies or errors may prompt the FDA to require re-analyses or even new studies, leading to substantial delays.

Expert Tip: Implement rigorous data management and auditing processes to verify the accuracy and consistency of all data points before submission. Leveraging modern data validation tools can also help. Engage your medical writers early (as early as you can, embargo process permitting) in the process of producing your Tables, Listings, and Figures to help spot any programming or other issues early.

6. Delays in Preclinical Studies

Preclinical issues, such as toxicity concerns or incomplete animal studies, can delay your transition into the clinical phases or even trigger a clinical hold by the FDA.

Expert Tip: Plan preclinical studies with sufficient buffers for unforeseen issues. Collaborate closely with CROs and ensure that all preclinical data supports your clinical plan. Leverage newer meeting types (e.g., INTERACT meeting) to allow for feedback as early in the development process as possible as well as other meeting types (e.g., Type C or Type D meeting) to discuss specific issues.

7. Suboptimal Regulatory Strategy

A poorly planned regulatory strategy, such as underestimating the complexity of rolling submissions or selecting the wrong approval pathway, can significantly impact your timeline.

Expert Tip: Develop a flexible regulatory strategy that aligns with your product’s characteristics as well as the competitive landscape. Consider using regulatory experts with experience in accelerated pathways like Priority Review or Breakthrough Therapy Designation.

8. Poor Communication with Contract Research Organizations (CROs)

Delays often occur due to poor communication or misalignment between the sponsor and CROs. Mismanagement of timelines or clinical trial milestones can extend your development period.

Expert Tip: Establish clear contracts, set realistic timelines, and maintain constant communication with your CROs. Regular updates and milestone tracking help prevent delays. Leverage escalation processes as needed to help navigate issues early before they become rate limiting.

9. Mismanagement of Regulatory Pathways and Designations

Regulatory pathways and special designations, such as Priority Review, Breakthrough Therapy, Fast Track, or Orphan Drug Status, can expedite approval processes. However, mismanagement of these pathways—by failing to meet milestones, missing required submissions, or misunderstanding designation criteria—can cause delays or impact the business goals in terms of expected return from investing in pursuing a specific pathway.

Expert Tip: Align your regulatory strategy with the most suitable pathway for your product. Engage with regulatory experts early on to ensure all deadlines, documentation requirements, and clinical data align with the chosen designation. Continually monitor progress to ensure compliance with the criteria for maintaining your designation status.

10. Inadequate Response to Information Requests

Once your BLA or NDA is under review, the FDA may issue Information Requests (IRs). A delayed or inadequate response can extend the review timeline.

Expert Tip: Be proactive in anticipating potential IRs by ensuring your dossier is well supported with data and documentation. Assign a dedicated team to manage IRs to ensure rapid and thorough responses. Anticipate key questions and proactively answer them in the application or discuss the approach with the team proactively.

Final Thoughts

Navigating the BLA or NDA submission process is challenging, with many risks that can delay your timeline. By engaging early with the FDA, maintaining data integrity, and developing a well-structured regulatory strategy, you can mitigate most common pitfalls. Leveraging expert advice and proactive planning will help keep your project on track and improve your chances of success.

Need help with your regulatory strategy or regulatory planning? Reach out to us at Reach out to us at [email protected] or 888-760-9906.

Read more about writing regulatory submissions!